RFEM’s Biosimilars IPR Dashboard provides current information on IPR proceedings related to proposed biosimilar...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK]
Avastin®
-
-
On February 2, 2018, U.S. District Judge George H. Wu granted Genentech’s motion to dismiss a complaint brought by Amgen in the Central...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
The FDA has only approved eight biosimilar products to date. The second most recently approved biosimilar is Mvasi (bevacizumab-awwb),...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Biologic drugs are quickly reshaping the pharmaceutical landscape as they dominate the drug market in annual sales revenue. Abbvie’s...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Novartis’ First CAR-T Cell Therapy Tisagenlecleucel (CTL019) The FDA’s Oncologic Drug Advisory Committee (“ODAC”) held a public...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Fujifilm Kyowa Kirin Biologics announced that its Medical Marketing Application (“MMA”) for FKB327, a biosimilar to AbbVie’s Humira®...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
The FDA announced yesterday that the Oncologic Drug Advisory Committee (“ODAC”) has scheduled a public meeting to review ABP 215,...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Genentech filed suit against Amgen this past February when a dispute arose between the parties during the first step of the “patent...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Hospira, Inc. (“Hospira”) filed a petition with the Patent Trial and Appeal Board (“PTAB”) on September 9, 2016, for inter partes...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK]